NASDAQ:VERU Veru Q3 2026 Earnings Report $2.33 -0.04 (-1.69%) Closing price 08/5/2026 04:00 PM EasternExtended Trading$2.30 -0.03 (-1.29%) As of 08/5/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Veru EPS ResultsActual EPSN/AConsensus EPS -$0.34Beat/MissN/AOne Year Ago EPSN/AVeru Revenue ResultsActual RevenueN/AExpected Revenue$1.70 millionBeat/MissN/AYoY Revenue GrowthN/AVeru Announcement DetailsQuarterQ3 2026Date8/10/2026TimeBefore Market OpensConference Call DateMonday, August 10, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Veru Earnings HeadlinesVeru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight LossAugust 4 at 8:30 AM | globenewswire.comVeru Inc. Announces August 10, 2026 Conference Call to Discuss Fiscal Third Quarter Results and Business UpdateAugust 3 at 8:51 AM | quiverquant.comQThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing. | Porter & Company (Ad)Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10thAugust 3 at 8:30 AM | globenewswire.comVeru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors ConferenceJuly 30, 2026 | globenewswire.comShort Interest in Veru Inc. (NASDAQ:VERU) Rises By 105.7%July 29, 2026 | americanbankingnews.comSee More Veru Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Veru? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veru and other key companies, straight to your email. Email Address About VeruVeru (NASDAQ:VERU) is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development. The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19. In parallel, Veru is developing toremifene, a selective estrogen receptor modulator repurposed to address chemotherapy-induced side effects and support women’s health applications. The company’s pipeline also encompasses exploratory programs aimed at targeting key drivers of cancer progression and acute inflammatory responses. Founded in 2010 (formerly operating as Veru Healthcare) by Dr. Mark A. Enyedy, who serves as President and Chief Executive Officer, Veru has conducted clinical studies across North America, Europe and Asia. The company maintains collaborations with academic institutions and contract research organizations to execute multi-center trials, and it has secured manufacturing partnerships to support planned commercial supply. Veru’s leadership team combines expertise in pharmaceutical development, regulatory affairs and oncology drug commercialization to guide late-stage program advancement.View Veru ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SpaceX: Love the Company, But the Stock Is a Harder CallAMD’s Post-Earnings Drop May Be the Opportunity Investors WantedMeta’s Earnings Drop Shows Wall Street Wants More Than Ad GrowthUlta's Growth Is Real, But So Are the RisksBWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth StoryCoreWeave Powers Up: The Asia Infrastructure GrabPalantir Soars 30% After Blockbuster Earnings—Is the Rally Just Getting Started? Upcoming Earnings Airbnb (8/6/2026)Warner Bros. Discovery (8/6/2026)Monster Beverage (8/6/2026)Canadian Natural Resources (8/6/2026)ConocoPhillips (8/6/2026)Cheniere Energy (8/6/2026)Petroleo Brasileiro S.A.- Petrobras (8/6/2026)Targa Resources (8/6/2026)Aflac (8/6/2026)Howmet Aerospace (8/6/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
